Ratings by Wedbush (Robert Driscoll)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/2/2026 | Revolution | RVMD | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2026 | Aprea | APRE | Maintain | Outperform (N/A) |
|
Details | ||
| 5/5/2026 | Pyxis Oncology Inc. | PYXS | New Coverage | Outperform (N/A) |
1.76 (2.83) |
60.8% | Details | |
| 4/13/2026 | Ideaya Biosciences | IDYA | Maintain | Outperform (N/A) |
|
Details | ||
| 4/13/2026 | Replimune Group | REPL | Downgrade | Neutral (Outperform) |
4.76 (11.37) |
138.87% | Details | |
| 3/23/2026 | Avalo Therapeutics Inc. | AVTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/6/2026 | Day One Biopharmaceuticals | DAWN | Downgrade | Neutral (Outperform) |
12.78 (21.53) |
68.47% | Details | |
| 2/26/2026 | Eikon Therapeutics Inc. | EIKN | New Coverage | Underperform (N/A) |
14.89 (11.94) |
-19.81% | Details | |
| 2/24/2026 | Arvinas Inc. | ARVN | Maintain | Neutral (N/A) |
|
Details | ||
| 2/18/2026 | Ideaya Biosciences | IDYA | Maintain | Outperform (N/A) |
|
Details | ||
| 2/13/2026 | Tyra Biosciences | TYRA | Maintain | Outperform (N/A) |
|
Details | ||
| 12/19/2025 | Werewolf Therapeutics Inc. | HOWL | Downgrade | Neutral (Outperform) |
0.65 (0.31) |
-52.31% | Details | |
| 12/16/2025 | Monte Rosa Therapeutics | GLUE | Maintain | Outperform (N/A) |
|
Details | ||
| 12/16/2025 | Tyra Biosciences | TYRA | Maintain | Outperform (N/A) |
|
Details | ||
| 12/11/2025 | CG Oncology | CGON | New Coverage | Outperform (N/A) |
41.74 (68.15) |
63.27% | Details | |
| 10/23/2025 | Tango Therapeutics Inc. | TNGX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/20/2025 | Replimune Group | REPL | Upgrade | Outperform (Neutral) |
4.50 (11.37) |
152.67% | Details | |
| 9/18/2025 | Arvinas Inc. | ARVN | Maintain | Neutral (N/A) |
|
Details | ||
| 9/11/2025 | Revolution | RVMD | Maintain | Outperform (N/A) |
|
Details | ||
| 7/22/2025 | Replimune Group | REPL | Downgrade | Neutral (Outperform) |
12.32 (4.50) |
-63.47% | Details | |
| 7/14/2025 | Catalyst Biosciences | CBIO | New Coverage | Outperform (N/A) |
12.96 (16.72) |
29.01% | Details | |
| 3/20/2025 | Elevation Oncology | ELEV | Downgrade | Neutral (Outperform) |
0.48 (0.37) |
-22.92% | Details | |
| 3/12/2025 | Arvinas Inc. | ARVN | Downgrade | Neutral (Outperform) |
8.30 (8.43) |
1.57% | Details | |
| 3/7/2025 | Black Diamond Therapeutics | BDTX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/26/2025 | Geron Corporation | GERN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/21/2025 | Avalo Therapeutics Inc. | AVTX | New Coverage | Outperform (N/A) |
6.99 (19.62) |
180.69% | Details | |
| 2/18/2025 | Arcus Biosciences | RCUS | Maintain | Outperform (N/A) |
|
Details | ||
| 2/12/2025 | Replimune Group | REPL | Maintain | Outperform (N/A) |
|
Details | ||
| 1/10/2025 | IGM Biosciences | IGMS | Downgrade | Neutral (Outperform) |
6.20 (1.27) |
-79.52% | Details | |
| 11/21/2024 | Kura Oncology | KURA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/7/2024 | Revolution | RVMD | Maintain | Outperform (N/A) |
|
Details | ||
| 10/1/2024 | IGM Biosciences | IGMS | Maintain | Outperform (N/A) |
|
Details | ||
| 8/12/2024 | Zentalis Pharmaceuticals | ZNTL | Upgrade | Neutral (Underperform) |
3.00 (4.66) |
55.33% | Details | |
| 7/30/2024 | Day One Biopharmaceuticals | DAWN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/30/2024 | Corbus Pharmaceuticals | CRBP | New Coverage | Outperform (N/A) |
58.06 (9.25) |
-84.07% | Details | |
| 6/18/2024 | Zentalis Pharmaceuticals | ZNTL | Downgrade | Underperform (Neutral) |
8.39 (4.66) |
-44.46% | Details | |
| 5/23/2024 | Tango Therapeutics Inc. | TNGX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/9/2024 | CytomX Therapeutics | CTMX | Upgrade | Outperform (Neutral) |
4.19 (3.76) |
-10.26% | Details | |
| 5/8/2024 | Janux Therapeutics | JANX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/19/2024 | Cullinan Oncology Inc. | CGEM | Maintain | Outperform (N/A) |
|
Details | ||
| 4/11/2024 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/11/2024 | Alpine Immune Sciences | ALPN | Downgrade | Neutral (Outperform) |
47.04 (64.97) |
38.12% | Details | |
| 4/8/2024 | Black Diamond Therapeutics | BDTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/27/2024 | Aprea | APRE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/6/2024 | Elevation Oncology | ELEV | Maintain | Outperform (N/A) |
|
Details | ||
| 2/27/2024 | Janux Therapeutics | JANX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/27/2024 | Revolution | RVMD | Maintain | Outperform (N/A) |
|
Details | ||
| 2/15/2024 | Cullinan Oncology Inc. | CGEM | New Coverage | Outperform (N/A) |
17.91 (17.94) |
0.17% | Details | |
| 2/15/2024 | Monte Rosa Therapeutics | GLUE | New Coverage | Outperform (N/A) |
4.26 (23.42) |
449.77% | Details | |
| 2/8/2024 | Replimune Group | REPL | Maintain | Outperform (N/A) |
|
Details | ||
| 1/30/2024 | Arcus Biosciences | RCUS | Maintain | Outperform (N/A) |
|
Details | ||
| 1/17/2024 | Ideaya Biosciences | IDYA | Maintain | Outperform (N/A) |
|
Details | ||
| 1/4/2024 | Revolution | RVMD | New Coverage | Outperform (N/A) |
27.99 (188.10) |
572.03% | Details | |
| 12/6/2023 | IGM Biosciences | IGMS | Maintain | Outperform (N/A) |
|
Details | ||
| 12/5/2023 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/5/2023 | Replimune Group | REPL | Maintain | Outperform (N/A) |
|
Details | ||
| 11/14/2023 | IGM Biosciences | IGMS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2023 | CytomX Therapeutics | CTMX | Upgrade | Outperform (Neutral) |
1.28 (3.76) |
193.75% | Details | |
| 11/8/2023 | Zentalis Pharmaceuticals | ZNTL | Downgrade | Neutral (Outperform) |
10.20 (4.66) |
-54.31% | Details | |
| 11/7/2023 | Day One Biopharmaceuticals | DAWN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/23/2023 | Arvinas Inc. | ARVN | Upgrade | Outperform (Neutral) |
14.83 (8.43) |
-43.16% | Details | |
| 8/24/2023 | Werewolf Therapeutics Inc. | HOWL | New Coverage | Outperform (N/A) |
2.46 (0.65) |
-73.58% | Details | |
| 8/15/2023 | Alpine Immune Sciences | ALPN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/14/2023 | Atreca Inc. | BCEL | Downgrade | Neutral (Outperform) |
0.56 (0.09) |
-83.93% | Details | |
| 6/30/2023 | Tyra Biosciences | TYRA | New Coverage | Outperform (N/A) |
16.69 (30.73) |
84.12% | Details | |
| 6/27/2023 | Black Diamond Therapeutics | BDTX | Upgrade | Outperform (Neutral) |
1.84 (2.12) |
15.22% | Details | |
| 6/27/2023 | Adicet Bio Inc. | ACET | Maintain | Outperform (N/A) |
|
Details | ||
| 6/16/2023 | Surface Oncology | SURF | Downgrade | Neutral (Outperform) |
0.74 (1.07) |
44.59% | Details | |
| 6/5/2023 | Elevation Oncology | ELEV | Maintain | Outperform (N/A) |
|
Details | ||
| 5/26/2023 | Zentalis Pharmaceuticals | ZNTL | Maintain | Outperform (N/A) |
|
Details | ||
| 4/24/2023 | Ideaya Biosciences | IDYA | Maintain | Outperform (N/A) |
|
Details | ||
| 4/6/2023 | Janux Therapeutics | JANX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/10/2023 | Arvinas Inc. | ARVN | Maintain | Neutral (N/A) |
|
Details | ||
| 1/9/2023 | Day One Biopharmaceuticals | DAWN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/4/2023 | Geron Corporation | GERN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/21/2022 | Imago Biosciences Inc | IMGO | Downgrade | Neutral (Outperform) |
17.40 (36.01) |
106.95% | Details | |
| 11/15/2022 | Atreca Inc. | BCEL | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2022 | Tango Therapeutics Inc. | TNGX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/4/2022 | Elevation Oncology | ELEV | Maintain | Outperform (N/A) |
|
Details | ||
| 11/2/2022 | Surface Oncology | SURF | Maintain | Outperform (N/A) |
|
Details | ||
| 10/28/2022 | Imago Biosciences Inc | IMGO | New Coverage | Outperform (N/A) |
16.54 (36.01) |
117.71% | Details | |
| 10/28/2022 | Geron Corporation | GERN | New Coverage | Outperform (N/A) |
2.39 (1.41) |
-41% | Details | |
| 8/4/2022 | Arcus Biosciences | RCUS | Maintain | Outperform (N/A) |
|
Details | ||
| 7/8/2022 | Aprea | APRE | New Coverage | Outperform (N/A) |
0.83 (0.76) |
-8.43% | Details | |
| 7/7/2022 | CytomX Therapeutics | CTMX | Downgrade | Neutral (Outperform) |
1.97 (3.76) |
90.86% | Details | |
| 6/13/2022 | Day One Biopharmaceuticals | DAWN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/16/2022 | Harpoon Therapeutics | HARP | Upgrade | Outperform (Neutral) |
2.00 (23.01) |
1050.5% | Details | |
| 5/9/2022 | Arvinas Inc. | ARVN | Downgrade | Neutral (Outperform) |
45.68 (8.43) |
-81.55% | Details | |
| 5/6/2022 | Elevation Oncology | ELEV | Maintain | Outperform (N/A) |
|
Details | ||
| 3/29/2022 | Black Diamond Therapeutics | BDTX | Downgrade | Neutral (Outperform) |
2.76 (2.12) |
-23.19% | Details | |
| 3/17/2022 | Cyteir Therapeutics | CYT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/8/2022 | Entasis Therapeutics | ETTX | Downgrade | Neutral (Outperform) |
1.69 (2.19) |
29.59% | Details | |
| 3/4/2022 | Elevation Oncology | ELEV | Maintain | Outperform (N/A) |
|
Details | ||
| 2/18/2022 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/21/2021 | CytomX Therapeutics | CTMX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/15/2021 | Compass Therapeutics | CMPX | New Coverage | Outperform (N/A) |
3.28 (2.18) |
-33.54% | Details | |
| 12/13/2021 | Foghorn Therapeutics | FHTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/19/2021 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 11/19/2021 | Arcus Biosciences | RCUS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2021 | IGM Biosciences | IGMS | Upgrade | Outperform (Neutral) |
52.96 (1.27) |
-97.6% | Details | |
| 10/19/2021 | Entasis Therapeutics | ETTX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/7/2021 | Tango Therapeutics Inc. | TNGX | New Coverage | Outperform (N/A) |
12.93 (29.33) |
126.84% | Details | |
| 8/17/2021 | Black Diamond Therapeutics | BDTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/6/2021 | Surface Oncology | SURF | Maintain | Outperform (N/A) |
|
Details | ||
| 8/5/2021 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/22/2021 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/20/2021 | Elevation Oncology | ELEV | New Coverage | Outperform (N/A) |
12.10 (0.37) |
-96.94% | Details | |
| 7/13/2021 | Cyteir Therapeutics | CYT | New Coverage | Outperform (N/A) |
19.65 (3.02) |
-84.63% | Details | |
| 6/21/2021 | Day One Biopharmaceuticals | DAWN | New Coverage | Outperform (N/A) |
21.00 (12.78) |
-39.14% | Details | |
| 6/7/2021 | Harpoon Therapeutics | HARP | Downgrade | Neutral (Outperform) |
15.86 (23.01) |
45.08% | Details | |
| 5/6/2021 | Entasis Therapeutics | ETTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/19/2021 | Idera Pharmaceuticals | IDRA | Downgrade | Neutral (Outperform) |
5.21 (0.43) |
-91.75% | Details | |
| 3/11/2021 | Harpoon Therapeutics | HARP | Maintain | Outperform (N/A) |
|
Details | ||
| 3/8/2021 | Arbutus Biopharma | ABUS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/4/2021 | Five Prime Therapeutics | FPRX | Downgrade | Neutral (Outperform) |
21.26 (38.00) |
78.74% | Details | |
| 2/25/2021 | Kura Oncology | KURA | Maintain | Outperform (N/A) |
|
Details | ||
| 2/5/2021 | Replimune Group | REPL | Maintain | Outperform (N/A) |
|
Details | ||
| 1/21/2021 | Ideaya Biosciences | IDYA | Maintain | Outperform (N/A) |
|
Details | ||
| 1/20/2021 | Zentalis Pharmaceuticals | ZNTL | New Coverage | Outperform (N/A) |
49.13 (4.66) |
-90.51% | Details | |
| 12/22/2020 | IGM Biosciences | IGMS | Downgrade | Neutral (Outperform) |
82.94 (1.27) |
-98.47% | Details | |
| 12/17/2020 | Surface Oncology | SURF | Maintain | Outperform (N/A) |
|
Details | ||
| 12/14/2020 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/17/2020 | Foghorn Therapeutics | FHTX | New Coverage | Outperform (N/A) |
16.05 (5.11) |
-68.16% | Details | |
| 11/9/2020 | Cidara Therapeutics | CDTX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/16/2020 | Aceto Corp. | ACET | New Coverage | Outperform (N/A) |
13.51 (8.79) |
-34.94% | Details | |
| 10/14/2020 | Replimune Group | REPL | Maintain | Outperform (N/A) |
|
Details | ||
| 10/7/2020 | Ideaya Biosciences | IDYA | New Coverage | Outperform (N/A) |
12.89 (39.46) |
206.13% | Details | |
| 8/28/2020 | Surface Oncology | SURF | New Coverage | Outperform (N/A) |
5.46 (1.07) |
-80.4% | Details | |
| 8/17/2020 | Cidara Therapeutics | CDTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/12/2020 | Arbutus Biopharma | ABUS | Maintain | Outperform (N/A) |
|
Details | ||
| 8/6/2020 | Harpoon Therapeutics | HARP | Maintain | Outperform (N/A) |
|
Details | ||
| 7/7/2020 | Corvus Pharmaceuticals | CRVS | Maintain | Outperform (N/A) |
|
Details | ||
| 6/22/2020 | Five Prime Therapeutics | FPRX | Upgrade | Outperform (Neutral) |
4.40 (21.26) |
383.18% | Details | |
| 6/19/2020 | Alpine Immune Sciences | ALPN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/3/2020 | Replimune Group | REPL | Maintain | Outperform (N/A) |
|
Details | ||
| 6/1/2020 | Harpoon Therapeutics | HARP | Maintain | Outperform (N/A) |
|
Details | ||
| 5/27/2020 | Arcus Biosciences | RCUS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/19/2020 | Arbutus Biopharma | ABUS | Upgrade | Outperform (Neutral) |
1.87 (4.98) |
166.31% | Details | |
| 5/8/2020 | CytomX Therapeutics | CTMX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2020 | Arcus Biosciences | RCUS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2020 | Kura Oncology | KURA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/1/2020 | Corvus Pharmaceuticals | CRVS | Maintain | Outperform (N/A) |
|
Details | ||
| 4/28/2020 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/22/2020 | IGM Biosciences | IGMS | New Coverage | Outperform (N/A) |
58.54 (1.27) |
-97.83% | Details | |
| 4/22/2020 | Atreca Inc. | BCEL | New Coverage | Outperform (N/A) |
15.00 (0.09) |
-99.4% | Details | |
| 3/24/2020 | CytomX Therapeutics | CTMX | Upgrade | Outperform (Neutral) |
4.93 (3.76) |
-23.73% | Details | |
| 3/19/2020 | Nabriva Therapeutics AG | NBRV | Downgrade | Neutral (Outperform) |
0.50 (1.42) |
184% | Details | |
| 3/16/2020 | Idera Pharmaceuticals | IDRA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/13/2020 | Corvus Pharmaceuticals | CRVS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/12/2020 | Entasis Therapeutics | ETTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/6/2020 | Cidara Therapeutics | CDTX | Maintain | (N/A) |
|
Details | ||
| 3/6/2020 | Cidara Therapeutics | CDTX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/18/2020 | Five Prime Therapeutics | FPRX | Downgrade | Neutral (Outperform) |
4.53 (38.00) |
738.85% | Details | |
| 12/19/2019 | Paratek Pharmaceuticals | PRTK | Maintain | Outperform (N/A) |
|
Details | ||
| 11/21/2019 | Cidara Therapeutics | CDTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2019 | CytomX Therapeutics | CTMX | Downgrade | Neutral (Outperform) |
5.95 (4.93) |
-17.14% | Details | |
| 10/4/2019 | Arbutus Biopharma | ABUS | Maintain | Neutral (N/A) |
|
Details | ||
| 9/25/2019 | Arvinas Inc. | ARVN | New Coverage | Outperform (N/A) |
24.41 (8.43) |
-65.46% | Details | |
| 9/4/2019 | Cidara Therapeutics | CDTX | Upgrade | Outperform (Neutral) |
1.68 (221.38) |
13077.38% | Details | |
| 8/20/2019 | Nabriva Therapeutics AG | NBRV | Maintain | Outperform (N/A) |
|
Details | ||
| 6/17/2019 | Kura Oncology | KURA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/17/2019 | Cidara Therapeutics | CDTX | Downgrade | Neutral (Outperform) |
2.05 (1.68) |
-18.05% | Details | |
| 5/9/2019 | Paratek Pharmaceuticals | PRTK | Maintain | Outperform (N/A) |
|
Details | ||
| 4/25/2019 | Replimune | REPL | New Coverage | Outperform (N/A) |
0.00 (12.32) |
0% | Details | |
| 3/7/2019 | Idera Pharmaceuticals | IDRA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/6/2019 | Paratek Pharmaceuticals | PRTK | Maintain | Outperform (N/A) |
|
Details | ||
| 3/5/2019 | Harpoon Therapeutics | HARP | New Coverage | Outperform (N/A) |
16.20 (23.01) |
42.04% | Details | |
| 3/1/2019 | Cidara Therapeutics | CDTX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/27/2019 | CytomX Therapeutics | CTMX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/17/2019 | Five Prime Therapeutics | FPRX | Upgrade | Outperform (Neutral) |
10.24 (4.53) |
-55.76% | Details | |
| 11/12/2018 | Achaogen | AKAO | Downgrade | Neutral (Outperform) |
2.65 (0.11) |
-95.85% | Details | |
| 10/22/2018 | Entasis Therapeutics | ETTX | New Coverage | Outperform (N/A) |
7.44 (2.19) |
-70.56% | Details | |
| 10/15/2018 | Arbutus Biopharma | ABUS | Upgrade | Neutral (Underperform) |
4.11 (4.98) |
21.17% | Details | |
| 10/9/2018 | Arbutus Biopharma | ABUS | Downgrade | Underperform (Neutral) |
9.09 (4.11) |
-54.79% | Details | |
| 10/9/2018 | Arcus Biosciences | RCUS | New Coverage | Outperform (N/A) |
13.84 (30.15) |
117.85% | Details | |
| 8/13/2018 | Arbutus Biopharma | ABUS | Maintain | Neutral (N/A) |
|
Details |
